Skip to content
Bomb Report – Lifestyle
Author:
Freenome, Inc.
FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test
August 12, 2026
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
July 27, 2026
Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection
July 20, 2026